Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Altamira Therapeutics Ltd (NQ: CYTO )

0.8791 +0.0597 (+7.29%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 26, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Altamira Therapeutics Ltd

< Previous 1 2 3 Next >
Altamira Therapeutics Reports Positive Top-Line Data from Bentrio Clinical Trial in Seasonal Allergic Rhinitis
Via ACCESSWIRE
Altamira Therapeutics Provides Business Update, Reports FY 2022 Financial Results
Via ACCESSWIRE
Altamira Therapeutics to Host Fiscal Year 2022 Financial Results and Business Update Call on May 16th 2023
Via ACCESSWIRE
Altamira Therapeutics CEO & Chairman to Present at Sidoti Micro-Cap Virtual Conference May 10-11
Via ACCESSWIRE
Altamira Therapeutics Announces Publication of Positive Results from Phase 2 Trial with AM-125 in Acute Vestibular Syndrome in Leading Peer Reviewed Journal
Via ACCESSWIRE
Altamira Therapeutics Positions its Patented SemaPhore mRNA Delivery Platform as Versatile and Efficient Alternative to Lipid Nanoparticles
Via ACCESSWIRE
Altamira Therapeutics Reports Positive Conclusions from Independent Meta-Analysis of Clinical Studies with Betahistine in Treatment of Most Common Cause of Vertigo
Via ACCESSWIRE
Altamira Therapeutics’ SemaPhore Delivery Platform Shows Significant Synergis-tic Effects of ZBTB46 mRNA with PD1 Immunotherapy in Control of Tumor Growth in Animal Model
From Altamira Therapeutics Ltd
Via GlobeNewswire
Altamira Therapeutics’ SemaPhore RNA Delivery Platform Drives Effective Treatment of Osteoarthritis with mRNA in Animal Model
Via ACCESSWIRE
Altamira Therapeutics’ (NASDAQ: CYTO) Clinical Data on Bentrio Showing Strong Nasal Residence and Rheological Properties
Altamira Therapeutics, Ltd. (NASDAQ: CYTO) is engaged within the research and development of RNA-based therapies for extrahepatic targets and unmet 
Via Spotlight Growth
Clinical Study Demonstrates Bentrio's Superior Nasal Residence Time and Rheological Properties
Via ACCESSWIRE
Altamira Therapeutics Files Provisional Patent Application for OligoPhore Nanoparticles Targeting Different KRAS Mutations in Cancer Treatment
From Altamira Therapeutics Ltd
Via GlobeNewswire
Altamira Therapeutics to Report Bentrio Clinical Data, in House Dust Mite and Grass Pollen Allergic Rhinitis, at Feb. 25 AAAAI Annual Meet-ing
Via ACCESSWIRE
Altamira Therapeutics to Present at Two Upcoming RNA Therapeutics Conferences in Q1 2023
Via ACCESSWIRE
Altamira Therapeutics Provides Business Update
From Altamira Therapeutics Ltd
Via GlobeNewswire
Altamira Therapeutics Provides Update on Clinical Trials with Bentrio
From Altamira Therapeutics Ltd
Via GlobeNewswire
Altamira Therapeutics to Present at 2nd Annual mRNA-Based Therapeutics Summit Europe Conference January 24th to 26th
From Altamira Therapeutics Ltd
Via GlobeNewswire
Altamira Therapeutics Provides Year-End 2022 Business Update
From Altamira Therapeutics Ltd
Via GlobeNewswire
Altamira Therapeutics Reaches Midpoint for Enrollment in Clinical Trial with Bentrio in Seasonal Allergic Rhinitis in Australia
Via ACCESSWIRE
Altamira Therapeutics Provides Business Update and First Half 2022 Financial Results
From Altamira Therapeutics Ltd
Via GlobeNewswire
Altamira Therapeutics Announces Launch of Bentrio in Hong Kong by its Partner Nuance Pharma
From Altamira Therapeutics Ltd
Via GlobeNewswire
In Vivo Data Presented at AHA Conference Demonstrates Altamira Therapeutics' SemaPhore mRNA Delivery Platform to Effectively Help Preserve Atherosclerotic Plaque Stability
Via ACCESSWIRE
Altamira Therapeutics to Participate at TIDES Europe Oligonucleotide and Peptide Therapeutics Hybrid Event
From Altamira Therapeutics Ltd
Via GlobeNewswire
Altamira Therapeutics Regains Listing Compliance with NASDAQ Minimum Bid Requirement
From Altamira Therapeutics Ltd
Via GlobeNewswire
Data Published in Peer-Reviewed Journal Demonstrate Protective Effects of Altamira’s Bentrio under Controlled Grass Pollen Exposure
From Altamira Therapeutics Ltd
Via GlobeNewswire
Altamira Therapeutics Announces Reverse Stock Split
From Altamira Therapeutics Ltd
Via GlobeNewswire
Altamira Therapeutics Announces Divestiture of Inner Ear Development Assets
From Altamira Therapeutics Ltd
Via GlobeNewswire
Altamira Therapeutics to Participate at RNA Leaders USA Congress
From Altamira Therapeutics Ltd
Via GlobeNewswire
Altamira Therapeutics Continue Bentrio Clinical Trial for Seasonal Allergic Rhinitis in Australia
From Altamira Therapeutics Ltd
Via GlobeNewswire
Altamira Therapeutics’ Delivery Platform with siRNA Shown to be Effective Treatment for Osteoarthritis as Published in Peer-Reviewed Journal
•Independent peer-reviewed study confirms high potential for OligoPhoreTM delivery platform in RNA-based treatments for osteoarthritis •Knock down of JMJD3 gene remarkably mitigated severity of joint... 
From Altamira Therapeutics Ltd
Via GlobeNewswire
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.